Palisade Bio (PALI) 10-Q12 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2013	Oct. 31, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'Neuralstem, Inc.	'
Entity Central Index Key	'0001357459	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'CUR	'
Entity Common Stock, Shares Outstanding	'	76,662,839
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
ASSETS	'	'
Cash and cash equivalents	$16,401,728	$7,443,773
Billed and unbilled receivables	7,500	3,333
Deferred financing fees, current portion	575,377	0
Prepaid expenses	343,973	205,651
Total current assets	17,328,578	7,652,757
Property and equipment, net	253,562	230,397
Patent filing fees, net	1,047,940	807,357
Deferred financing fees, net of current portion	470,769	0
Other assets	64,862	59,568
Total assets	19,165,711	8,750,079
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable and accrued expenses	1,212,578	1,199,662
Accrued bonus expense	462,882	465,865
Current portion of long term debt, net of discount	1,986,154	0
Derivative instruments	1,311,880	0
Other current liabilities	174,345	90,776
Total current liabilities	5,147,839	1,756,303
Long term debt, net of discount and current portion	5,661,336	0
Other long term liabilities	89,650	21,143
Total liabilities	10,898,825	1,777,446
STOCKHOLDERS' EQUITY	'	'
Preferred stock, 7,000,000 shares authorized, zero shares issued and outstanding	0	0
Common stock, $0.01 par value; 150 million shares authorized, 76,662,839 and 68,189,314 shares outstanding in 2013 and 2012, respectively	766,628	681,893
Additional paid-in capital	132,617,006	114,884,915
Accumulated other comprehensive income	6,101	0
Accumulated deficit	-125,122,849	-108,594,175
Total stockholders' equity	8,266,886	6,972,633
Total liabilities and stockholders' equity	$19,165,711	$8,750,079

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred stock, shares authorized	7,000,000	7,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares outstanding	76,662,839	68,189,314

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues	$2,500	$170,833	$107,500	$405,208
Operating expenses:	'	'	'	'
Research and development costs	1,847,403	1,385,478	5,502,137	4,406,538
General and administrative expenses	1,707,690	1,280,606	4,184,740	3,264,146
Depreciation and amortization	81,393	87,908	181,991	164,154
Total operating expenses	3,636,486	2,753,992	9,868,868	7,834,838
Operating loss	-3,633,986	-2,583,159	-9,761,368	-7,429,630
Other income (expense):	'	'	'	'
Interest income	18,776	5,411	45,336	21,601
Interest expense	-448,943	-335	-936,471	-1,789
Warrant modification expense	-1,945,214	0	-5,017,156	0
Loss from change in fair value of derivative instruments	-677,883	0	-859,682	0
Litigation settlement	293	692	667	3,265
Total other income (expense)	-3,052,971	5,768	-6,767,306	23,077
Net loss	-6,686,957	-2,577,391	-16,528,674	-7,406,553
Net loss per share - basic and diluted (in dollars per share)	($0.09)	($0.04)	($0.23)	($0.14)
Weighted average common shares outstanding - basic and diluted (in shares)	72,986,698	58,363,721	70,533,035	54,751,377
Comprehensive loss:	'	'	'	'
Net loss	-6,686,957	-2,577,391	-16,528,674	-7,406,553
Foreign currency translation adjustment	6,101	0	6,101	0
Comprehensive loss	($6,680,856)	($2,577,391)	($16,522,573)	($7,406,553)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
Condensed Consolidated Statements of Cash Flows (USD $)	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net loss	($16,528,674)	($7,406,553)
Adjustments to reconcile net loss to cash used in operating activities:	'	'
Depreciation and amortization	181,991	164,154
Share based compensation expense	2,080,740	1,187,692
Amortization of deferred financing fees and debt discount	462,794	0
Warrant modification expense	5,017,156	0
Loss from change in fair value of derivative instruments	859,682	0
Changes in operating assets and liabilities:	'	'
Billed and unbilled receivables	-4,167	233,542
Prepaid expenses	38,849	117,838
Other assets	-5,172	15,861
Accounts payable and accrued expenses	-97,128	-342,339
Accrued bonus expense	-94,558	37,812
Other current liabilities	-18,541	8,807
Other long term liabilities	-8,651	23,750
Net cash used in operating activities	-8,115,679	-5,959,436
Cash flows from investing activities:	'	'
Patent filing fees	-325,783	-158,115
Purchase of property and equipment	-118,938	-30,203
Net cash used in investing activities	-444,721	-188,318
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock from warrants exercised, net of issuance costs	5,836,346	0
Proceeds from sale of common stock and warrants, net of issuance costs	4,241,640	13,685,408
Proceeds from long term debt, net of issuance costs	7,551,329	0
Payments on notes payable	-81,362	-16,272
Prepayment of equity financing fees	-35,000	0
Net cash provided by financing activities	17,512,953	13,669,136
Effects of exchange rates on cash	5,402	0
Net increase in cash and cash equivalents	8,957,955	7,521,382
Cash and cash equivalents, beginning of period	7,443,773	2,352,013
Cash and cash equivalents, end of period	16,401,728	9,873,395
Supplemental disclosure of cash flows information:	'	'
Cash paid for interest	399,960	1,789
Supplemental schedule of non cash investing and financing activities:	'	'
Issuance of common stock for vendor services, net of returned shares for amended agreement	0	152,288
Issuance of warrants for vendor services	658,326	0
Issuance of common stock for executive bonuses	0	141,119
Issuance of common stock for fees related to debt issuance	396,234	0
Issuance of warrants for fees related to debt issuance	452,187	0
Financing of insurance premiums through note payable	183,472	146,452
Issuance of common stock for cashless exercise of warrants	587,500	0
Issuance of common stock for exercise of restricted stock units	$0	$330

Basis_of_Presentation_and_Liqu

Basis of Presentation and Liquidity	9 Months Ended
Basis of Presentation and Liquidity	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	'
	Note 1. Basis of Presentation and Liquidity
	In management’s opinion, the accompanying condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2012, has been derived from audited financial statements as of that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (SEC). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed financial statements are read in conjunction with the Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC on March 15, 2013, and as may be amended. Certain prior period amounts have been reclassified to conform to the current year presentation.

	Neuralstem, Inc. is referred to as “Neuralstem,” the “Company,” “us,” or “we” throughout this report. Beginning in the quarter ended September 30, 2013, our investment in, and the operations of, our wholly-owned and controlled subsidiary located in China are consolidated in our condensed consolidated financial statements; previously, all investments in China were expensed as incurred. The impacts of this change were not material in any period presented.

	The Company's operations currently do not generate significant cash. The Company's management does not know when this will change. The Company has spent and will continue to spend substantial funds in the research, development, clinical and pre-clinical testing of the Company's stem cell and small molecule product candidates with the goal of ultimately obtaining approval from the United States Food and Drug Administration (the “FDA”), to market and sell our products. While we believe our long-term cash position is inadequate to fund all of the costs associated with the full range of testing and clinical trials required by the FDA for our core product candidates, we anticipate that our available cash and expected income will be sufficient to finance our current activities at least through September 30, 2014.

	No assurance can be given that (i) we will be able to expand our operations prior to FDA approval of our proposed products, or (ii) that FDA approval will ever be granted for our product candidates, or (iii) that if FDA approval is granted, that we will ever be able to sell our products or be profitable.

Significant_Accounting_Policie

Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2. Significant Accounting Policies and Recent Accounting Pronouncements
	Use of Estimates
	The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The condensed financial statements include significant estimates for the value and expected economic life of our licensed technology, our net operating loss for tax purposes, the fair value of our derivative instruments and our share-based compensation related to employees and directors, consultants and investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.

	Fair Value Measurements
	The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, accounts payable and certain accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness is estimated based on the quoted prices for the same or similar issues or on the current interest rates offered to the Company for debt of the same remaining maturities. The fair values of our derivative instruments and certain other accrued expenses are estimated using level 3 unobservable inputs. See Note 3 for further details.

	Foreign Currency Translation
	The functional currency of our wholly owned foreign subsidiary is their local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of are accumulated in other comprehensive income, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss.

	Cash, Cash Equivalents and Credit Risk
	Cash equivalents consist of investments in low risk, highly liquid money market funds and certificates of deposit with original maturities of 90 days or less. Cash deposited with banks and other financial institutions may exceed the amount of insurance provided on such deposits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.

	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. We limit our credit and liquidity risks through our investment policy and through regular reviews of our portfolio against our policy. To date, we have not experienced any loss or lack of access to cash in our operating accounts or to our cash equivalents.

	Revenue Recognition
	Historically, our revenue has been derived primarily from (i) selling treated samples for gene expression data from stem cell experiments, (ii) providing services under various contracts and grants and (iii) licensing the use of our intellectual property to third parties. Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery of goods and services has occurred, the price is fixed and determinable, and collection is reasonably assured.

	Research and Development
	Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated with pre-clinical development of treatments for central nervous system diseases, and with our clinical trials for both pharmaceutical and stem cell based treatments.

	Income (Loss) per Common Share
	Basic income (loss) per common share is computed by dividing total net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period.

	For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options, restricted share units and stock warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. The Company’s unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator.

	For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three- and nine-month periods ended September 30, 2013 and 2012. A total of approximately 36.1 million potential dilutive shares have been excluded in the calculation of diluted net income per share for the three- and nine-month periods ended September 30, 2013 and 35.2 million potential dilutive shares have been excluded in the calculation of diluted net income per share for the three- and nine-month periods ended September 30, 2012, as their inclusion would be anti-dilutive.

	Share-Based Compensation
	We account for share-based compensation at fair value. Share-based compensation cost for stock options and warrants is determined at the grant date using an option pricing model that uses level 3 unobservable inputs; share-based compensation cost for restricted stock and restricted stock units is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period.

	Intangible and Long-Lived Assets
	We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. During the three- and nine-month periods ended September 30, 2013 and 2012, no impairment losses were recognized.

	Income Taxes
	We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. Tax periods open to examination by the Internal Revenue Service include the calendar years ended December 31, 2012, 2011 and 2010.

	Significant New Accounting Pronouncements
	We have evaluated all Accounting Standards Updates through the date the financial statements were issued and believe the adoption of any new accounting and disclosure requirements will not have a material impact to our results of operations or financial position.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 3. Fair Value Measurements
	Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These levels are:

	⋅ Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

	⋅ Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques (e.g. the Black-Scholes model) for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and forward and spot prices for currencies and commodities.

	⋅ Level 3 – inputs are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models.

	Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
	The Company has segregated its financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below (in thousands).

	The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of the Company’s funds. The fair value of other short-term financial instruments (primarily accounts receivable, inventory, prepaid expenses and other current assets, and accounts payable and accrued expenses) approximate their carrying values because of their short-term nature. The fair value of our long-term indebtedness approximates its carrying value.

	The Company has stock purchase warrants issued in conjunction with its March 2013 debt offering (see Notes 4 and 5) that are accounted for as derivative instruments whose fair market value is determined using Level 3 inputs. The Company also has issued certain stock options that are subject to shareholder approval that are recorded as an accrued liability carried at fair market value using Level 3 inputs. These inputs include expected term, expected dividends and expected volatility.

	The following table identifies the carrying amounts of such assets and liabilities:

		30-Sep-13
		Level 1		Level 2		Level 3		Total
	Liabilities
	Stock options subject to shareholder approval	$	-	$	-	$	109,602	$	109,602
	Derivative instruments - stock purchase warrants		-		-		1,311,880		1,311,880
		$	-	$	-	$	1,421,482	$	1,421,482

	The Company did not have any Level 3 financial assets or liabilities measured at fair value at December 31, 2012.

	The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs for the nine months ended September 30, 2013:


		Derivative		Stock Options
		Instruments - Stock
		Purchase Warrants
	Balance at December 31, 2012	$	-	$	-
	Issuance		452,198		35,000
	Change in fair value		859,682		74,602
	Balance at September 30, 2013	$	1,311,880	$	109,602

	The losses resulting from the changes in the fair value of the derivative instruments are classified as the “change in the fair value of derivative instruments” in the accompanying condensed statements of operations. The change in fair value of the contingent stock options is classified as share-based compensation. The fair values of both the stock purchase warrants and the contingent stock options are determined based on the Black-Scholes option pricing model, and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value; increases in expected term, anticipated volatility and expected dividends generally result in increased in fair value, while decreases in these unobservable inputs generally result in decreases in fair value.

	Non-Financial Assets and Liabilities Measure at Fair Value on a Recurring Basis
	The Company has no non-financial assets and liabilities that are measured at fair value on a recurring basis.

	Non-Financial Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
	The Company measures its long-lived assets, including property and equipment and patent filing fees, at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. No such fair value impairment was recognized in the nine-months ended September 30, 2013 or 2012.

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 4. Debt
	In March 2013, the Company entered into a Loan and Security agreement for an initial $8 million term loan with an additional $2 million of borrowing capacity if certain conditions involving new partnerships are met. The loan is collateralized by substantially all of the Company’s assets, including our intellectual property.

	The loan provides for interest at a variable rate based on prime with a floor of 11% and matures in June 2016. Our weighted average interest on outstanding borrowings was 11% for the nine months ended September 30, 2013. The loan calls for interest only payments through December 2013 at which time principal and interest payments begin through maturity. The interest only period and maturity could both be extended by three months if the additional borrowing capacity was drawn on; such capacity was not drawn on. The loan resulted in net proceeds of approximately $7,551,000 after origination and other cash fees and expenses related to the closing of the loan.

	In conjunction with the loan agreement, the Company issued to the lender a five-year common stock purchase warrant to purchase 648,809 shares at an exercise price of $1.0789 per share. This warrant contains non-standard anti-dilution protection and, consequently, is being accounted for as a derivative instrument and is recorded at fair market value each period (see Note 3). The allocation of proceeds to this warrant resulted in a debt discount which is being amortized as interest expense over the term of the debt using the effective interest method.

	The Company also incurred expenses with various third parties in connection with the debt issuance, consisting of approximately $449,000 in cash, 350,650 shares of common stock valued at approximately $396,000, and a five-year common stock purchase warrant to purchase 648,798 shares at an exercise price of $1.07892 per share. The warrant is classified as equity. Fees related to the debt offering are recorded as deferred financing fees and are being amortized as interest expense over the term of the debt using the effective interest method.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 5. Stockholders’ Equity
	We have granted share-based compensation awards to employees, board members and service providers. Awards may consist of common stock, restricted common stock, restricted common stock units, warrants, or stock options. Our stock options and warrants have lives of up to ten years from the grant date. The awards vest either upon the grant date or over varying periods of time. The stock options we grant provide for option exercise prices equal to or greater than the fair market value of the common stock on the date of the grant. Restricted stock units grant the holder the right to receive fully paid common shares with various restrictions on the holder’s ability to transfer the shares. As of September 30, 2013, we have approximately 32,000 shares of common stock reserved for issuance of such awards under our equity compensation plans.

	Share-based compensation expense included in the condensed statements of operations for the three and nine months ended September 30, 2013 and 2012 was as follows:

			Three Months Ended September 30,
			2013			2012
	Research and development costs		$	241,934		$	193,558
	General and administrative expenses			765,519			293,142
	Total		$	1,007,453		$	486,700

			Nine Months Ended September 30,
			2013			2012
	Research and development costs		$	690,199		$	462,380
	General and administrative expenses			1,390,541			725,312
	Total		$	2,080,740		$	1,187,692

	Included in general and administrative expenses for each of the nine months ended September 30, 2013 and 2012 is approximately $11,000 and $180,000, respectively related to consulting expenses where we paid consultants in shares of common stock. Additionally, included in expenses for the nine months ended September 30, 2012, is approximately $141,000, respectively related to research and development expenses that we paid for with shares of common stock.

	Stock Options. A summary of stock option activity during the nine months ended September 30, 2013 and related information is included in the table below:

			Number of Options		Weighted-			Weighted-		Aggregate
					Average			Average		Intrinsic Value
					Exercise			Remaining
					Price			Contractual
								Life (in years)
	Outstanding at January 1, 2013		14,787,287		$	1.98		6.1		$	1,926,000
	Granted		1,502,579		$	1.12
	Exercised		-		$	-
	Forfeited		-		$	-
	Outstanding at September 30, 2013		16,289,866		$	1.9		5.7		$	17,479,303

	Exercisable at September 30, 2013		12,364,648		$	2.17		4.7		$	10,865,493

	Vested and expected to vest		16,289,866		$	1.9		5.7		$	17,479,303

	Range of Exercise Prices		Number of Options		Weighted-			Weighted-		Aggregate
			Outstanding		Average			Average		Intrinsic Value
					Exercise			Remaining
					Price			Contractual
								Life (in years)
	$0.50 - $1.00		5,400,000		$	0.73		5.7		$	10,674,000
	$1.01 - $2.00		4,182,999		$	1.19		7.9		$	6,342,186
	$2.01 - $3.00		1,903,534		$	2.47		5		$	463,117
	$3.01 - $4.00		4,803,333		$	3.59		4		$	-
			16,289,866		$	1.9		5.7		$	17,479,303

	The Company uses the Black-Scholes option pricing model to calculate the fair value of options. Significant assumptions used in this model include:

			Nine Months Ended September 30,
			2013		2012
	Annual dividend		-		-
	Expected life (in years)		3.0 - 6.0		2.0 - 4.0
	Risk free interest rate		0.51% - 1.01%		0.29% - 0.65%
	Expected volatility		65.1% - 75.2%		55.5% - 70.6%

	The 1,502,579 options granted in the first nine months of 2013 had a weighted average grant date fair value of $0.69. Unrecognized compensation expense for unvested stock options outstanding at September 30, 2013 was approximately $2,065,000 and will be recognized over an average of 1.9 years.

	Restricted Stock Units. We have granted restricted stock units (RSUs) to certain employees and directors that entitle the holders to receive shares of our common stock upon vesting of the RSUs, and subject to certain restrictions regarding the exercise of the RSUs. The fair value of restricted stock units granted is based upon the market price of the underlying common stock as if they were vested and issued on the date of grant.

	A summary of our restricted stock unit activity for the nine months ended September 30, 2013 is as follows:

			Number of		Weighted-
RSU's			Average
			Grant Date
			Fair Value
Outstanding at January 1, 2013		371,491			$	2.1
Granted		30,702			$	1.14
Vested and converted to common shares		-			$	-
Forfeited		-		$	-
Outstanding at September 30, 2013		402,193		$	2.03

Exercisable at September 30, 2013		363,585		$	2.05

Unrecognized compensation expense for unvested restricted stock units outstanding at September 30, 2013 was approximately $69,000 and will be recognized over an average of 0.4 years.

Common Stock Purchase Warrants. Warrants to purchase common stock were issued to certain officers, directors, stockholders and service providers. In addition, warrants were issued in conjunction with the March 2013 debt transaction and the September 2013 registered direct offering.

A summary of warrant activity for the nine months ended September 30, 2013 follows:

		Number of		Weighted-			Weighted-		Aggregate
		Shares		Average			Average		Intrinsic
		Underlying		Exercise			Remaining		Value
		Warrants		Price			Contractual
							Life (in years)
Outstanding at January 1, 2013		19,840,176		$	2.08		3.5		$	854,649
Granted		7,761,211		$	1.83		4.3
Exercised		-5,202,935		$	1.29
Forfeited		-2,599,633		$	3.12
Outstanding at September 30, 2013		19,798,819		$	1.97		3.6		$	18,508,411

Exercisable at September 30, 2013		18,204,219		$	1.8		3.2		$	17,376,245

The 7,761,211 common stock purchase warrants granted in the nine months ended September 30, 2013 had a weighted average grant date fair value of $0.82.

Common Stock
In February 2012, the Company completed a registered direct placement of 5,200,000 shares of common stock at a price of $1.00 per share, and 5,200,000 common stock purchase warrants, each with an exercise price of $1.02 per share and exercisable starting six months from the issuance date for a term of five years. The Company received aggregate gross proceeds of $5,200,000; net proceeds were approximately $4,877,000. The warrants are classified within equity.

In March 2012, pursuant to the terms of a 2010 consulting agreement, we issued: (i) 180,000 common shares; and (ii) a common stock purchase warrant entitling the holder to purchase 510,821 shares of common stock at $0.99 per share as compensation for business advisory services. The warrant was exercisable immediately, expires on January 6, 2022, and is freely assignable in whole or in part. We also agreed to register the shares underlying the warrant with the SEC for resale. The warrant is classified within equity.

In August 2012, the Company completed an underwritten public offering of 6,900,000 shares of common stock at a price of $0.40 per share. The Company received aggregate gross proceeds of $2,760,000; net proceeds were approximately $2,441,000. In connection with the offering, the Company issued a common stock purchase warrant to the underwriters for the purchase of up to 300,000 shares of its common stock; the warrant has an exercise price of $0.50 per share and is exercisable for five years. The warrant is classified within equity.

In September 2012, the Company completed a registered direct placement of 7,000,000 shares of common stock at a price of $1.00 per share. The Company received aggregate gross proceeds of $7,000,000; net proceeds were approximately $6,368,000. In connection with the offering, the Company issued a common stock purchase warrant to the placement agent for the purchase of up to 350,000 shares of its common stock; the warrant has an exercise price of $1.25 per share and is exercisable for five years. The warrant is classified within equity.

In October of 2012, we entered into a consulting agreement related to the marketing of NS-189, our small molecule compound to other pharmaceutical and drug development companies. As partial consideration for the services to be rendered, we issued an aggregate of 25,000 shares of our common stock which vests over the initial five month term of the agreement.

In December 2012, we issued 200,000 shares of common stock as a result of a warrant holder exercising their common stock purchase warrants. The stock was issued at $1.02 and generated approximately $204,000 in net proceeds.

In January and February 2013, we issued 258,000 shares of common stock as a result of certain warrant holders exercising their common stock purchase warrants. The stock was issued at $1.25 per share and generated approximately $323,000 in net proceeds. In conjunction with the exercises we modified the warrants to reduce the exercise price to $1.25 and issued 258,000 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction of the strike price on the original warrants. Such expense is classified as warrant modification expense. The warrants are classified within equity.

In March 2013, we issued 350,650 shares of common stock and 1,297,607 common stock purchase warrants to various parties in conjunction with our debt transaction (see Note 4).

In May 2013, we issued 440,000 shares of common stock as a result of a certain warrant holder exercising their common stock purchase warrants. The stock was issued at $1.07 per share and generated approximately $433,000 in net proceeds. In conjunction with the exercise we modified the warrants to reduce the exercise price to $1.07 and issued 440,000 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in May 2016. We recognized expense for the value of the replacement warrants and the reduction of the strike price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified within equity.

In May 2013, we issued 689,675 shares of common stock as a result of certain warrant holders exercising their common stock purchase warrants. The stock was issued at $1.25 per share and generated approximately $844,000 in net proceeds. In conjunction with the exercises we modified the warrants to reduce the exercise price to $1.25 and issued 689,675 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction of the strike price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified within equity.

In May and June 2013, we issued 378,809 shares of common stock as a result of certain warrant holders exercising their common stock purchase warrants. The stock was issued at $1.25 per share and generated approximately $474,000 in net proceeds. In conjunction with the exercise we issued 378,809 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants; such expense is classified as warrant modification expense. The warrants are classified within equity.

In May and June 2013, we issued 300,000 shares of our common stock to a warrant holder as a result of their exercising their common stock purchase warrants. The stock was issued at $1.02 and generated approximately $306,000 in net proceeds.

In July 2013, we issued 942,520 shares of our common stock to a warrant holder as a result of their exercising their common stock purchase warrants. The stock was issued at $1.25 per share and generated approximately $1,178,000 in net proceeds. In conjunction with the exercises we modified 782,005 of the warrants to reduce the exercise price to $1.25 and issued 942,520 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction of the strike price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified within equity.

In July 2013, we issued 100,000 shares of common stock as a result of a warrant holder exercising their common stock purchase warrants. The stock was issued at $1.02 and generated approximately $102,000 in net proceeds.

In September 2013, we issued 1,448,798 shares of common stock as a result of certain warrant holders exercising their common stock purchase warrants. The stock was issued at $1.25 per share (800,000 shares) and $1.08 per share (648,798 shares) and generated approximately $1,700,000 in net proceeds. In conjunction with the exercise we issued an additional 72,440 shares of our common stock as a commission for exercise. We recognized an expense for the value of the additional common stock; such expense is classified as warrant modification expense.

In September 2013, we issued 244,000 shares of common stock as a result of certain warrant holders exercising their common stock purchase warrants. 240,000 shares of stock were issued at $2.13 while 4,000 shares of stock were issued at $1.56. The exercises generated approximately $477,000 net proceeds.

In September 2013, we issued 401,133 shares of our common stock as a result of certain warrant holders exercising the cashless exercise provision of their common stock purchase warrants with an average strike price of $0.90. Such exercises resulted in 248,867 warrants being forfeited and resulted in no net proceeds to the Company.

In September 2013, the Company completed a registered direct placement of 2,847,500 shares of common stock at a price of $1.60 per share. The Company received aggregate gross proceeds of $4,556,000; net proceeds were approximately $4,242,000. In connection with the offering, the Company issued 1,423,750 common stock purchase warrants to purchase 1,423,750 shares of our common stock; the warrant has an exercise price of $2.00 and is exercisable for five years. Additionally, we issued a common stock purchase warrant to the placement agent for the purchase of up to 170,850 shares of its common stock; the warrant has an exercise price of $2.00 per share and is exercisable for 19 months. The warrants are classified within equity.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 6. Commitments and Contingencies
	We are parties to legal proceedings that we believe to be ordinary, routine litigation incidental to the business of present or former operations. It is management’s opinion, based on the advice of counsel, that the ultimate resolution of such litigation will not have a material adverse effect on our financial condition, results of operations or cash flows.

	On May 7, 2008, we filed suit against StemCells, Inc., StemCells California, Inc. (collectively "StemCells") and Neurospheres Holding Ltd. in U.S. District Court for the District of Maryland, alleging that U.S. Patent No. 7,361,505 (the "'505 patent") is invalid, not infringed, and unenforceable. See Civil Action No. 08-1173. On May 13, 2008, we filed an Amended Complaint seeking declaratory judgment that U.S. Patent No. 7,155,418 (the "'418 patent") is invalid and not infringed and that certain statements made by our CEO are not trade libel or do not constitute unfair competition. On September 11, 2008, StemCells filed its answer asserting counterclaims of infringement for the '505 patent, the 418 patent, and state law claims for trade libel and unfair competition. This case was consolidated with the 2006 litigation discussed below and it is not known when, nor on what basis, this matter will be concluded.

	On July 28, 2006, StemCells, Inc., filed suit against Neuralstem, Inc. in the U.S. District Court in Maryland, alleging that Neuralstem has been infringing, contributing to the infringement of, and or inducing the infringement of four patents allegedly owned by or exclusively licensed to StemCells. See Civil Action No. 06-1877. We answered the Complaint denying infringement, asserting that the patents are invalid, asserting that we have intervening rights based on amendments made to the patents during reexamination proceedings, and further asserting that some of the patents are unenforceable due to inequitable conduct. Neuralstem has also asserted counterclaims that StemCells has engaged in anticompetitive conduct in violation of antitrust laws. On February 28, 2011, Neuralstem filed a Motion to Dismiss for lack of standing and concurrently filed a Motion for Leave to Amend its Answer and Counterclaim to allege that StemCells is not the exclusive licensee of the patents-in-suit and also that Neuralstem has obtained a non-exclusive license to the patents-in-suit. In addition, before the Court decided Neuralstem’s Motion to Dismiss for lack of standing, StemCells filed a motion for summary judgment on the issue standing. Neuralstem responded to that motion and cross-moved for summary judgment on the issue of standing. The Court further issued its Markman Order on August 12, 2011. On August 26, 2011, StemCells moved for reconsideration of two terms construed in the Markman Order and that motion remains pending. On April 6, 2012, the Court granted Neuralstem's Motion for Leave to Amend to assert lack of standing and denied Neuralstem's Motion to Dismiss and Motion for Summary Judgment without prejudice. The Court also denied StemCells' Motion for Summary Judgment with prejudice. The Court has stayed all other matters regarding the merits of the suit pending resolution of the question of standing.

	On October 22, 2013, the Court ordered the parties to submit a joint briefing schedule regarding the issue of standing. It is anticipated that the parties will complete briefing the standing issue sometime in January of 2014. Thereafter, the Court will decide whether StemCells has standing to pursue its patent infringement claims. It is unknown when or how the Court will resolve these issues.

	In connection with the January 2011 settlement of our litigation with ReNeuron, Ltd. we are entitled to, among other things, future milestone and royalty payments based on ReNeuron’s development of certain products. We assert that one of the milestones has been achieved as of June 30, 2013 and consequently we are due a milestone payment of $250,000. We are currently negotiating with ReNeuron as they contend that the milestone has not been met. To date, we have not recognized any revenue for this milestone.

Subsequent_Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 7. Subsequent Events
	The Company has performed an evaluation of subsequent events through the date the accompanying financial statements were issued and did not identify any material subsequent transactions that require disclosure.

Significant_Accounting_Policie1

Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The condensed financial statements include significant estimates for the value and expected economic life of our licensed technology, our net operating loss for tax purposes, the fair value of our derivative instruments and our share-based compensation related to employees and directors, consultants and investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.

Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value Measurements
	The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, accounts payable and certain accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness is estimated based on the quoted prices for the same or similar issues or on the current interest rates offered to the Company for debt of the same remaining maturities. The fair values of our derivative instruments and certain other accrued expenses are estimated using level 3 unobservable inputs. See Note 3 for further details.

Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign Currency Translation
	The functional currency of our wholly owned foreign subsidiary is their local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of are accumulated in other comprehensive income, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss.

Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash, Cash Equivalents and Credit Risk
	Cash equivalents consist of investments in low risk, highly liquid money market funds and certificates of deposit with original maturities of 90 days or less. Cash deposited with banks and other financial institutions may exceed the amount of insurance provided on such deposits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.

	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. We limit our credit and liquidity risks through our investment policy and through regular reviews of our portfolio against our policy. To date, we have not experienced any loss or lack of access to cash in our operating accounts or to our cash equivalents.

Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Historically, our revenue has been derived primarily from (i) selling treated samples for gene expression data from stem cell experiments, (ii) providing services under various contracts and grants and (iii) licensing the use of our intellectual property to third parties. Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery of goods and services has occurred, the price is fixed and determinable, and collection is reasonably assured.

Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated with pre-clinical development of treatments for central nervous system diseases, and with our clinical trials for both pharmaceutical and stem cell based treatments.

Earnings Per Share, Policy [Policy Text Block]	'
	Income (Loss) per Common Share
	Basic income (loss) per common share is computed by dividing total net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period.

	For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options, restricted share units and stock warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. The Company’s unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator.

	For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three- and nine-month periods ended September 30, 2013 and 2012. A total of approximately 36.1 million potential dilutive shares have been excluded in the calculation of diluted net income per share for the three- and nine-month periods ended September 30, 2013 and 35.2 million potential dilutive shares have been excluded in the calculation of diluted net income per share for the three- and nine-month periods ended September 30, 2012, as their inclusion would be anti-dilutive.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-Based Compensation
	We account for share-based compensation at fair value. Share-based compensation cost for stock options and warrants is determined at the grant date using an option pricing model that uses level 3 unobservable inputs; share-based compensation cost for restricted stock and restricted stock units is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period.

Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Intangible and Long-Lived Assets
	We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. During the three- and nine-month periods ended September 30, 2013 and 2012, no impairment losses were recognized.

Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. Tax periods open to examination by the Internal Revenue Service include the calender years ended December 31, 2012, 2011 and 2010.

New Accounting Pronouncements, Policy [Policy Text Block]	'
	Significant New Accounting Pronouncements
	We have evaluated all Accounting Standards Updates through the date the financial statements were issued and believe the adoption of any new accounting and disclosure requirements will not have a material impact to our results of operations or financial position.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	'
	The following table identifies the carrying amounts of such assets and liabilities:

		30-Sep-13
		Level 1		Level 2		Level 3		Total
	Liabilities
	Stock options subject to shareholder approval	$	-	$	-	$	109,602	$	109,602
	Derivative instruments - stock purchase warrants		-		-		1,311,880		1,311,880
		$	-	$	-	$	1,421,482	$	1,421,482

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs for the nine months ended September 30, 2013:


		Derivative		Stock Options
		Instruments - Stock
		Purchase Warrants
	Balance at December 31, 2012	$	-	$	-
	Issuance		452,198		35,000
	Change in fair value		859,682		74,602
	Balance at September 30, 2013	$	1,311,880	$	109,602

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	Share-based compensation expense included in the condensed statements of operations for the three and nine months ended September 30, 2013 and 2012 was as follows:


		Three Months Ended September 30,
		2013			2012
	Research and development costs	$	241,934		$	193,558
	General and administrative expenses		765,519			293,142
	Total	$	1,007,453		$	486,700

		Nine Months Ended September 30,
		2013			2012
	Research and development costs	$	690,199		$	462,380
	General and administrative expenses		1,390,541			725,312
	Total	$	2,080,740		$	1,187,692

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of stock option activity during the nine months ended September 30, 2013 and related information is included in the table below:

		Number of Options		Weighted-			Weighted-	Aggregate
				Average			Average	Intrinsic Value
				Exercise			Remaining
				Price			Contractual
							Life (in years)
	Outstanding at January 1, 2013	14,787,287		$	1.98		6.1	$	1,926,000
	Granted	1,502,579		$	1.12
	Exercised	-		$	-
	Forfeited	-		$	-
	Outstanding at September 30, 2013	16,289,866		$	1.9		5.7	$	17,479,303

	Exercisable at September 30, 2013	12,364,648		$	2.17		4.7	$	10,865,493

	Vested and expected to vest	16,289,866		$	1.9		5.7	$	17,479,303

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	Range of Exercise Prices	Number of Options		Weighted-			Weighted-	Aggregate
		Outstanding		Average			Average	Intrinsic Value
				Exercise			Remaining
				Price			Contractual
							Life (in years)
	$0.50 - $1.00	5,400,000		$	0.73		5.7	$	10,674,000
	$1.01 - $2.00	4,182,999		$	1.19		7.9	$	6,342,186
	$2.01 - $3.00	1,903,534		$	2.47		5	$	463,117
	$3.01 - $4.00	4,803,333		$	3.59		4	$	-
		16,289,866		$	1.9		5.7	$	17,479,303

Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Black Sholes Model [Table Text Block]	'
	The Company uses the Black-Scholes option pricing model to calculate the fair value of options. Significant assumptions used in this model include:

		Nine Months Ended September 30,
		2013		2012
	Annual dividend	-		-
	Expected life (in years)	3.0 - 6.0		2.0 - 4.0
	Risk free interest rate	0.51% - 1.01%		0.29% - 0.65%
	Expected volatility	65.1% - 75.2%		55.5% - 70.6%

Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	'
	A summary of our restricted stock unit activity for the nine months ended September 30, 2013 is as follows:

		Number of		Weighted-
		RSU's		Average
				Grant Date
				Fair Value
	Outstanding at January 1, 2013	371,491		$	2.1
	Granted	30,702		$	1.14
	Vested and converted to common shares	-		$	-
	Forfeited	-		$	-
	Outstanding at September 30, 2013	402,193		$	2.03

	Exercisable at September 30, 2013	363,585		$	2.05

Schedule Of Share Based Compensation Warrant Activity [Table Text Block]	'
	A summary of warrant activity for the nine months ended September 30, 2013 follows:

		Number of		Weighted-			Weighted-	Aggregate
		Shares		Average			Average	Intrinsic
		Underlying		Exercise			Remaining	Value
		Warrants		Price			Contractual
							Life (in years)
	Outstanding at January 1, 2013	19,840,176		$	2.08		3.5	$	854,649
	Granted	7,761,211		$	1.83		4.3
	Exercised	-5,202,935		$	1.29
	Forfeited	-2,599,633		$	3.12
	Outstanding at September 30, 2013	19,798,819		$	1.97		3.6	$	18,508,411

	Exercisable at September 30, 2013	18,204,219		$	1.8		3.2	$	17,376,245

Significant_Accounting_Policie2

Significant Accounting Policies and Recent Accounting Pronouncements (Details Textual)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Significant Accounting Policies [Line Items]	'	'	'	'
Policy For Maximum Maturity Days Of Investments Considered As Cash Equivalents	'	'	'90 days	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	36.1	35.2	36.1	35.2

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Derivatives, Fair Value [Line Items]	'	'
Stock options subject to shareholder approval	$109,602	$0
Derivative instruments	1,311,880	0
Derivative and Stock option Carry amount Liability Current And Noncurrent	1,421,482	'
Equity Option [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Stock options subject to shareholder approval	109,602	'
Warrant [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments	1,311,880	0
Fair Value, Inputs, Level 1 [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative and Stock option Carry amount Liability Current And Noncurrent	0	'
Fair Value, Inputs, Level 1 [Member] \| Equity Option [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Stock options subject to shareholder approval	0	'
Fair Value, Inputs, Level 1 [Member] \| Warrant [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments	0	'
Fair Value, Inputs, Level 2 [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative and Stock option Carry amount Liability Current And Noncurrent	0	'
Fair Value, Inputs, Level 2 [Member] \| Equity Option [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Stock options subject to shareholder approval	0	'
Fair Value, Inputs, Level 2 [Member] \| Warrant [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments	0	'
Fair Value, Inputs, Level 3 [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative and Stock option Carry amount Liability Current And Noncurrent	1,421,482	'
Fair Value, Inputs, Level 3 [Member] \| Equity Option [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Stock options subject to shareholder approval	109,602	'
Fair Value, Inputs, Level 3 [Member] \| Warrant [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments	$1,311,880	'

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	3 Months Ended		9 Months Ended
Fair Value Measurements (Details 1) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Derivatives, Fair Value [Line Items]	'	'	'	'
Balance at December 31, 2012	'	'	$0	'
Change in fair value	677,883	0	859,682	0
Balance at September 30, 2013	1,311,880	'	1,311,880	'
Balance at December 31, 2012	'	'	0	'
Issuance	'	'	35,000	'
Change in fair value	'	'	74,602	'
Balance at September 30, 2013	109,602	'	109,602	'
Warrant [Member]	'	'	'	'
Derivatives, Fair Value [Line Items]	'	'	'	'
Balance at December 31, 2012	'	'	0	'
Issuance	'	'	452,198	'
Change in fair value	'	'	859,682	'
Balance at September 30, 2013	$1,311,880	'	$1,311,880	'

Debt_Details_Textual

Debt (Details Textual) (USD $)	1 Months Ended	9 Months Ended
Debt (Details Textual) (USD $)	Mar. 31, 2013	Sep. 30, 2013
Debt Instrument [Line Items]	'	'
Debt Instrument, Face Amount	$8,000,000	'
Debt Instrument, Unused Borrowing Capacity, Amount	2,000,000	'
Debt Instrument, Interest Rate at Period End	'	11.00%
Debt Instrument, Maturity Date	'	30-Jun-16
Debt Instrument, Weighted Average Interest Rate	'	11.00%
Debt Instrument, Maturity Date, Description	'	'maturity could both be extended by three months if the additional borrowing capacity was drawn on
Proceeds from Debt, Net of Issuance Costs	'	7,551,000
Stock Issued During Period, Shares, New Issues	350,650	'
Warrant One [Member]	'	'
Debt Instrument [Line Items]	'	'
Number Of Common Stock Shares Granted By Issue Of Warrants	'	648,809
Exercise Price Per share Of Common Stock To Be Issued Upon Conversion Of Warrants	'	$1.08
Warrant Expiration Period	'	'5 years
Warrant Two [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Issuance Cost	'	449,000
Stock Issued During Period, Shares, New Issues	'	350,650
Number Of Common Stock Shares Granted By Issue Of Warrants	'	648,798
Exercise Price Per share Of Common Stock To Be Issued Upon Conversion Of Warrants	'	$1.08
Warrant Expiration Period	'	'5 years
Stock Issued During Period, Value, New Issues	'	$396,000

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended		9 Months Ended
Stockholders' Equity (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stockholders Equity [Line Items]	'	'	'	'
Total	$1,007,453	$486,700	$2,080,740	$1,187,692
Research and Development Expense [Member]	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'
Total	241,934	193,558	690,199	462,380
General and Administrative Expense [Member]	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'
Total	$765,519	$293,142	$1,390,541	$725,312

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	9 Months Ended
Stockholders' Equity (Details 1) (USD $)	Sep. 30, 2013
Stockholders Equity [Line Items]	'
Outstanding Number of Options, at January 1, 2013	14,787,287
Granted Number of Options	1,502,579
Exercised Number of Options	0
Forfeited Number of Options	0
Outstanding Number of Options, at September 30, 2013	16,289,866
Exercisable Number of Options, at September 30, 2013	12,364,648
Vested and expected to vest Number of Options	16,289,866
Outstanding Weighted-Average Exercise Price, at January 1, 2013	$1.98
Granted Weighted-Average Exercise Price	$1.12
Exercised Weighted-Average Exercise Price	$0
Forfeited Weighted-Average Exercise Price	$0
Outstanding Weighted-Average Exercise Price, at September 30, 2013	$1.90
Exercisable Weighted-Average Exercise Price, at September 30, 2013	$2.17
Vested and expected to vest Weighted-Average Exercise Price	$1.90
Outstanding Weighted-Average Remaining Contractual Life (in Years), at January 1, 2013	'6 years 1 month 6 days
Outstanding Weighted-Average Remaining Contractual Life (in Years), at September 30, 2013	'5 years 8 months 12 days
Exercisable Weighted-Average Remaining Contractual Life (in Years), at September 30, 2013	'4 years 8 months 12 days
Vested and expected to vest Weighted-Average Remaining Contractual Life (in Years)	'5 years 8 months 12 days
Outstanding Aggregate Intrinsic Value, at January 1, 2013	$1,926,000
Outstanding Aggregate Intrinsic Value, at September 30, 2013	17,479,303
Exercisable Aggregate Intrinsic Value, at September 30, 2013	10,865,493
Vested and expected to vest Aggregate Intrinsic Value	$17,479,303

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
Stockholders' Equity (Details 2) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Range One [Member]	Range Two [Member]	Range Three [Member]	Range Four [Member]
Stockholders Equity [Line Items]	'	'	'	'	'	'
Range of Exercise Price (Lower)	'	'	$0.50	$1.01	$2.01	$3.01
Range of Exercise Price (Upper)	'	'	$1	$2	$3	$4
Number of Options Outstanding	16,289,866	'	5,400,000	4,182,999	1,903,534	4,803,333
Weighted-Average Exercise Price	$1.90	$1.98	$0.73	$1.19	$2.47	$3.59
Weighted-Average Remaining Contractual Life (in Years)	'5 years 8 months 12 days	'6 years 1 month 6 days	'5 years 8 months 12 days	'7 years 10 months 24 days	'5 years	'4 years
Aggregate Intrinsic Value	$17,479,303	$1,926,000	$10,674,000	$6,342,186	$463,117	$0

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3)	9 Months Ended
Stockholders' Equity (Details 3)	Sep. 30, 2013	Sep. 30, 2012
Stockholders Equity [Line Items]	'	'
Annual dividend	0.00%	0.00%
Minimum [Member]	'	'
Stockholders Equity [Line Items]	'	'
Expected life (in years)	'3 years	'2 years
Risk free interest rate	0.51%	0.29%
Expected volatility	65.10%	55.50%
Maximum [Member]	'	'
Stockholders Equity [Line Items]	'	'
Expected life (in years)	'6 years	'4 years
Risk free interest rate	1.01%	0.65%
Expected volatility	75.20%	70.60%

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4) (Restricted Stock Units (RSUs) [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Restricted Stock Units (RSUs) [Member]	'
Stockholders Equity [Line Items]	'
Outstanding Number of RSU's at January 1, 2013	371,491
Granted Number of RSU's	30,702
Vested and converted to common shares Number of RSU's	0
Forfeited Number of RSU's	0
Outstanding Number of RSU's at September 30, 2013	402,193
Exercisable Number of RSU's at September 30, 2013	363,585
Outstanding Weighted-Average Grant Date Fair Value at January 1, 2013	$2.10
Granted Weighted-Average Grant Date Fair Value	$1.14
Vested and converted to common shares Weighted-Average Grant Date Fair Value	$0
Forfeited Weighted-Average Grant Date Fair Value	$0
Outstanding Weighted-Average Grant Date Fair Value at September 30, 2013	$2.03
Exercisable Weighted-Average Grant Date Fair Value at September 30, 2013	$2.05

Stockholders_Equity_Details_5

Stockholders' Equity (Details 5) (Warrant [Member], USD $)	9 Months Ended
Stockholders' Equity (Details 5) (Warrant [Member], USD $)	Sep. 30, 2013
Warrant [Member]	'
Stockholders Equity [Line Items]	'
Outstanding Number of Shares Underlying Warrants, at January 1, 2013	19,840,176
Granted Number of Shares Underlying Warrants	7,761,211
Exercised Number of Shares Underlying Warrants	-5,202,935
Forfeited Number of Shares Underlying Warrants	-2,599,633
Outstanding Number of Shares Underlying Warrants, at September 30, 2013	19,798,819
Exercisable Number of Shares Underlying Warrants, at September 30, 2013	18,204,219
Outstanding Weighted-Average Exercise Price, at January 1, 2013	$2.08
Granted Weighted-Average Exercise Price	$1.83
Exercised Weighted-Average Exercise Price	$1.29
Forfeited Weighted Average Exercise Price	$3.12
Outstanding Weighted-Average Exercise Price, at September 30, 2013	$1.97
Exercisable Weighted-Average Exercise Price, at September 30, 2013	$1.80
Outstanding Weighted-Average Remaining Contractual Life (in years), at January 1, 2013	'3 years 6 months
Granted Weighted-Average Remaining Contractual Life (in years)	'4 years 3 months 18 days
Outstanding Weighted-Average Remaining Contractual Life (in years), at September 30, 2013	'3 years 7 months 6 days
Exercisable Weighted-Average Remaining Contractual Life (in years), at September 30, 2013	'3 years 2 months 12 days
Outstanding Aggregate Intrinsic Value, at January 1, 2013	$854,649
Outstanding Aggregate Intrinsic Value, at September 30, 2013	18,508,411
Exercisable Aggregate Intrinsic Value, at September 30, 2013	$17,376,245

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

1 Months Ended

2 Months Ended

9 Months Ended

1 Months Ended

2 Months Ended

1 Months Ended

2 Months Ended

9 Months Ended

1 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Oct. 31, 2012

Sep. 30, 2012

Aug. 31, 2012

Feb. 29, 2012

Feb. 28, 2013

Sep. 30, 2013

Jul. 31, 2013

31-May-13

Sep. 30, 2013

Jul. 31, 2013

31-May-13

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2012

Sep. 30, 2013

Phase One [Member]

Phase Two [Member]

Phase three [Member]

Phase Four [Member]

Consulting Expenses [Member]

Research and Development Expense [Member]

Market Development Consulting Group [Member]

Minimum [Member]

Maximum [Member]

Common Stock [Member]

Private Placement [Member]

Phase One [Member]

Phase Two [Member]

Phase One [Member]

Phase Two [Member]

Phase One [Member]

Phase Four [Member]

Stockholders Equity [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance

32,000

Allocated Share-based Compensation Expense

$11,000

$180,000

$141,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

$0.69

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

$0.82

Shares Issued Direct Placement

7,000,000

5,200,000

Warrants Issued During Period

5,200,000

258,000

1,448,798

942,520

440,000

244,000

100,000

689,675

401,133

378,809

1,423,750

648,798

4,000

800,000

240,000

170,850

Class Of Warrant Or Right Exercise Price Of Warrants Issued

$1.25

$0.50

$1.02

$1.25

$1.07

$1.02

$1.25

$0.90

$0.99

$1.08

$1.56

$1.25

$2.13

Share Price

$1.02

$0.40

$1.25

$1.07

$1.25

Stock Issued During Period Share From Warrants In Conjunction With Debt Transaction

1,297,607

Proceeds from Issuance of Common Stock

7,000,000

2,760,000

5,200,000

Net proceeds received from issuance

204,000

6,368,000

2,441,000

4,877,000

323,000

1,700,000

1,178,000

433,000

477,000

102,000

844,000

474,000

4,242,000

306,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

350,000

300,000

510,821

Stock Issued During Period, Shares, New Issues

350,650

72,440

Issuance of common stock from warrants exercised (in shares)

200,000

258,000

942,520

440,000

689,675

378,809

300,000

Common Stock In Public Offering

6,900,000

Warrants Expiration Date

'2020-03-31

'2016-05-31

'2020-03-31

'2022-01-06

Class of Warrant or Right, Exercise Price of Warrants or Rights

1.25

1.02

Stock Issued During Period, Shares, Issued for Services

25,000

180,000

Warrants Modified During Period

782,005

Warrants Forfeited During Period

248,867

Stock Issued During Period Shares Placement

2,847,500

Warrants And Shares Issued Value Gross

4,556,000

Common Stock, Par or Stated Value Per Share

$0.01

$1.60

Stock or Unit Option Plan Expense

2,065,000

Compensation Expenses Unvested stock option term period

'1 year 10 months 24 days

Restricted Stock or Unit Expense

$69,000

Compensation Expenses Unvested Restricted Stock term period

'4 months 24 days

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	Jun. 30, 2013
Gain Contingencies [Line Items]	'
Gain Contingency, Unrecorded Amount	$250,000